Clinical trial

A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

NCT01625897

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-05-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2012-05-01Date precision: month

Registry last updated2026-01-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

MP-214DRUG

RisperidoneDRUG · verified · RxNorm: risperidone

Sponsors & collaborators

Tanabe Pharma Corporationlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01625897 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.